search
Back to results

GW823093C For The Treatment Of Type 2 Diabetes Mellitus

Primary Purpose

Diabetes Mellitus, Type 2

Status
Terminated
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
GW823093C A
GW823093C B
GW823093C C
Sponsored by
GlaxoSmithKline
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring GW823093C, diabetes, type 2 diabetes mellitus, DPP-IV inhibitor

Eligibility Criteria

20 Years - 74 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria: Type 2 diabetes mellitus. Managed by diet therapy or receiving treatment with oral anti-diabetic monotherapy (excluding TZD (Thiazolidinediones)) Exclusion criteria: Patients who have metabolic disease judged by investigator as a clinically significance Serious cardiovascular disease or serious hepatic disease

Sites / Locations

  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Placebo Comparator

Placebo Comparator

Placebo Comparator

Arm Label

GW823093C A

GW823093C B

GW823093C C

Arm Description

A=45 mg

B=30 mg

C=15 mg

Outcomes

Primary Outcome Measures

Efficacy variables Dose response (change from baseline in HbA1c) at stipulated date in each treatment group

Secondary Outcome Measures

Long term safety variables

Full Information

First Posted
August 30, 2006
Last Updated
August 30, 2018
Sponsor
GlaxoSmithKline
search

1. Study Identification

Unique Protocol Identification Number
NCT00370942
Brief Title
GW823093C For The Treatment Of Type 2 Diabetes Mellitus
Official Title
GW823093 Japan Phase IIa Mono
Study Type
Interventional

2. Study Status

Record Verification Date
August 2018
Overall Recruitment Status
Terminated
Why Stopped
Safety issue
Study Start Date
April 1, 2006 (undefined)
Primary Completion Date
November 1, 2006 (Actual)
Study Completion Date
November 25, 2006 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
GlaxoSmithKline

4. Oversight

5. Study Description

Brief Summary
This study was designed to find dose response and as extension in treatment of GW823093C.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
GW823093C, diabetes, type 2 diabetes mellitus, DPP-IV inhibitor

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
159 (Actual)

8. Arms, Groups, and Interventions

Arm Title
GW823093C A
Arm Type
Placebo Comparator
Arm Description
A=45 mg
Arm Title
GW823093C B
Arm Type
Placebo Comparator
Arm Description
B=30 mg
Arm Title
GW823093C C
Arm Type
Placebo Comparator
Arm Description
C=15 mg
Intervention Type
Drug
Intervention Name(s)
GW823093C A
Intervention Description
A=45 mg
Intervention Type
Drug
Intervention Name(s)
GW823093C B
Intervention Description
B=30 mg
Intervention Type
Drug
Intervention Name(s)
GW823093C C
Intervention Description
C=25 mg
Primary Outcome Measure Information:
Title
Efficacy variables Dose response (change from baseline in HbA1c) at stipulated date in each treatment group
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Long term safety variables
Time Frame
64 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
74 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Type 2 diabetes mellitus. Managed by diet therapy or receiving treatment with oral anti-diabetic monotherapy (excluding TZD (Thiazolidinediones)) Exclusion criteria: Patients who have metabolic disease judged by investigator as a clinically significance Serious cardiovascular disease or serious hepatic disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
GSK Clinical Trials
Organizational Affiliation
GlaxoSmithKline
Official's Role
Study Director
Facility Information:
Facility Name
GSK Investigational Site
City
Hokkaido
ZIP/Postal Code
051-0005
Country
Japan
Facility Name
GSK Investigational Site
City
Miyagi
ZIP/Postal Code
985-0852
Country
Japan
Facility Name
GSK Investigational Site
City
Tokyo
ZIP/Postal Code
130-0004
Country
Japan
Facility Name
GSK Investigational Site
City
Tokyo
ZIP/Postal Code
160-0017
Country
Japan
Facility Name
GSK Investigational Site

12. IPD Sharing Statement

Learn more about this trial

GW823093C For The Treatment Of Type 2 Diabetes Mellitus

We'll reach out to this number within 24 hrs